BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8454420)

  • 1. Interleukin-6 in myeloma/plasmacytoma.
    Suematsu S; Matsusaka T; Matsuda T; Hirano T; Kishimoto T
    Int Rev Exp Pathol; 1993; 34 Pt A():91-8. PubMed ID: 8454420
    [No Abstract]   [Full Text] [Related]  

  • 2. Extraosseous IL-6 transgenic mouse plasmacytoma sometimes lacks Myc-activating chromosomal translocation.
    McNeil N; Kim JS; Ried T; Janz S
    Genes Chromosomes Cancer; 2005 Jun; 43(2):137-46. PubMed ID: 15751044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insertion of Myc into Igh accelerates peritoneal plasmacytomas in mice.
    Park SS; Shaffer AL; Kim JS; duBois W; Potter M; Staudt LM; Janz S
    Cancer Res; 2005 Sep; 65(17):7644-52. PubMed ID: 16140930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of interleukin-6 in the pathogenesis of murine plasmacytoma and human multiple myeloma.
    Pattengale PK
    Am J Pathol; 1997 Sep; 151(3):647-9. PubMed ID: 9284811
    [No Abstract]   [Full Text] [Related]  

  • 5. Reduction of early B lymphocyte precursors in transgenic mice overexpressing the murine heat-stable antigen.
    Hough MR; Chappel MS; Sauvageau G; Takei F; Kay R; Humphries RK
    J Immunol; 1996 Jan; 156(2):479-88. PubMed ID: 8543797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoglobulin genes and the c-myc oncogene in plasmacytomagenesis.
    Potter M
    Mt Sinai J Med; 1986 Mar; 53(3):216-22. PubMed ID: 3084962
    [No Abstract]   [Full Text] [Related]  

  • 7. Lymph nodes and Peyer's patches of IL-6 transgenic BALB/c mice harbor T(12;15) translocated plasma cells that contain illegitimate exchanges between the immunoglobulin heavy-chain mu locus and c-myc.
    Kovalchuk AL; Kishimoto T; Janz S
    Leukemia; 2000 Jun; 14(6):1127-35. PubMed ID: 10865979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of major histocompatibility complex (MHC) to upregulation of anti-DNA antibody in transgenic mice.
    Song YW; Tsao BP; Hahn BH
    J Autoimmun; 1993 Feb; 6(1):1-9. PubMed ID: 8457281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice.
    Lattanzio G; Libert C; Aquilina M; Cappelletti M; Ciliberto G; Musiani P; Poli V
    Am J Pathol; 1997 Sep; 151(3):689-96. PubMed ID: 9284817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple genetic loci modify susceptibility to plasmacytoma-related morbidity in E(mu)-v-abl transgenic mice.
    Symons RC; Daly MJ; Fridlyand J; Speed TP; Cook WD; Gerondakis S; Harris AW; Foote SJ
    Proc Natl Acad Sci U S A; 2002 Aug; 99(17):11299-304. PubMed ID: 12149518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deletional remodeling of c-myc-deregulating chromosomal translocations.
    Kovalchuk AL; Müller JR; Janz S
    Oncogene; 1997 Nov; 15(19):2369-77. PubMed ID: 9393881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of immunoglobulin/c-myc recombinations in mice that are resistant to plasmacytoma induction.
    Müller JR; Jones GM; Potter M; Janz S
    Cancer Res; 1996 Jan; 56(2):419-23. PubMed ID: 8542601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perspectives on the origins of multiple myeloma and plasmacytomas in mice.
    Potter M
    Hematol Oncol Clin North Am; 1992 Apr; 6(2):211-23. PubMed ID: 1582969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated mutant frequencies in lymphoid tissues persist throughout plasmacytoma development in BALB/c.lambdaLIZ mice.
    Felix K; Kelliher KA; Bornkamm GW; Janz S
    Cancer Res; 1999 Aug; 59(15):3621-6. PubMed ID: 10446972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic control of sensitivity to Moloney leukemia virus in mice. IV. Phenotypic heterogeneity of the leukemic mice.
    Boyer B; Gisselbrecht S; Debre P; McKenzie I; Levy JP
    J Immunol; 1980 Oct; 125(4):1415-20. PubMed ID: 7410844
    [No Abstract]   [Full Text] [Related]  

  • 16. ABL-MYC retroviral infection elicits bone marrow plasma cell tumors in Bcl-X(L) transgenic mice.
    Linden M; Kirchhof N; Kvitrud M; Van Ness B
    Leuk Res; 2005 Apr; 29(4):435-44. PubMed ID: 15725478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anaplastic, plasmablastic, and plasmacytic plasmacytomas of mice: relationships to human plasma cell neoplasms and late-stage differentiation of normal B cells.
    Qi CF; Zhou JX; Lee CH; Naghashfar Z; Xiang S; Kovalchuk AL; Fredrickson TN; Hartley JW; Roopenian DC; Davidson WF; Janz S; Morse HC
    Cancer Res; 2007 Mar; 67(6):2439-47. PubMed ID: 17363561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strain-related cellular mechanisms as a determinant for susceptibility and resistance to PC induction.
    Sugiyama H; Silva S; Wang Y; Klein G
    Curr Top Microbiol Immunol; 1995; 194():93-7. PubMed ID: 7895526
    [No Abstract]   [Full Text] [Related]  

  • 19. Designer mice: the production of human antibody repertoires in transgenic animals.
    Brüggemann M; Davies NP; Rosewell IR
    Year Immunol; 1993; 7():33-40. PubMed ID: 8372511
    [No Abstract]   [Full Text] [Related]  

  • 20. AID and RAG1 do not contribute to lymphomagenesis in Emu c-myc transgenic mice.
    Nepal RM; Zaheen A; Basit W; Li L; Berger SA; Martin A
    Oncogene; 2008 Aug; 27(34):4752-6. PubMed ID: 18408759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.